Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: The COHERE collaboration

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1541-1550

  Smit, Colette ^a   Sterne, Jonathan A C ^b   Monforte, Antonella D'Arminio ^c   Puotti, Massimo ^d   De Wolf, Frank ^a   Peters, Lars ^e   Ledergerber, Bruno ^f   De Wit, Stephane ^g   Sambatakou, Hellen ^h   Rauch, Andri ⁱ   Dabis, Francois ^j  

^a STICHTING HIV MONITORING   (Netherlands)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c University Hospital San Paolo   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h Amacs   (Greece)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871865046     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2263     Document Type: Article

References (28)

1. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
3. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
4. Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2012; 13:89-97.
5. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
6. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008; 47:221-225 (Pubitemid 351172190)
7. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
8. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
9. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
11. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36. (Pubitemid 39179626)
12. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459. (Pubitemid 38988594)
13. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
14. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
15. Mocroft A, Rockstroh J, Soriano V, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38:1092-1097. (Pubitemid 44869287)
16. Rauch A, Egger M, Reichen J, Furrer H. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238-240. (Pubitemid 40189334)
17. Vogel M, Ahlenstiel G, Hintsche B, et al. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. Eur J Med Res 2010; 15:102-111.
18. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560. (Pubitemid 30660034)
19. Zinkernagel AS, von Wyl V, Ledergerber B, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006; 11:131-142.
20. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19:357-365.
21. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 2006; 24:585-591. (Pubitemid 44127839)
22. Murray MC, Barrios R, Zhang W, et al. Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Eur J Gastroenterol Hepatol 2011; 23:45-50.
23. +, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol 2006; 146:270-277.
24. Neau D, Galperine T, Legrand E, et al. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin. HIV Med 2003; 4:120-126. (Pubitemid 36582294)
25. Reiberger T, Payer BA, Kosi L, Heil PM, Rieger A, Peck-Radosavljevic M. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients. J Infect Dis 2011; 203:1802-1806.
26. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357:196-197. (Pubitemid 32108094)
27. Barreiro P, Labarga P, Martin-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11:869-877. (Pubitemid 44736178)
28. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384. (Pubitemid 41073955)